Abstract | OBJECTIVES: METHODS: RESULTS: Eight patients responded to treatment and achieved both the MITAX and CK levels objectives within 6 months of rituximab therapy. Five out of these 8 responders remained clinically stable at 12 months and CK levels were still reduced or normalised. Of note, 4 patients who did not respond were re-assessed and had their diagnoses corrected. All patients showed adequate B cell depletion (BCD) with re-population occurring for a 15.4 months average (range 3-42 months). Those simultaneously treated with cyclophosphamide achieved more long-lasting depletion (average 18.6 months). CONCLUSIONS: The heterogeneous clinical and serological characteristics of patients diagnosed with IIM probably explain why some, but not all patients respond to rituximab. Myositis overlap and anti- synthetase syndromes seem to respond better than other patient subsets.
|
Authors | Francisco Muñoz-Beamud, David A Isenberg |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2013 Nov-Dec
Vol. 31
Issue 6
Pg. 896-903
ISSN: 0392-856X [Print] Italy |
PMID | 24050676
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Biomarkers
- Immunologic Factors
- Rituximab
- Creatine Kinase
|
Topics |
- Adult
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage, adverse effects, therapeutic use)
- B-Lymphocytes
(drug effects, immunology)
- Biomarkers
(blood)
- Creatine Kinase
(blood)
- Drug Administration Schedule
- Female
- Humans
- Immunologic Factors
(administration & dosage, adverse effects, therapeutic use)
- Infusions, Intravenous
- Male
- Middle Aged
- Myositis
(blood, diagnosis, drug therapy, immunology)
- Remission Induction
- Retrospective Studies
- Rituximab
- Time Factors
- Treatment Outcome
|